MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study.

ABSTRACT: Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of alkylating agents, studies on melanoma outcome of patients treated with melphalan regional chemotherapy should consider this epigenetic change. This study aims to evaluate whether the survival of stage III melanoma patients treated with melphalan regional chemotherapy may be correlated with MGMT methylation status. The metastatic tissues of 27 stage III melanoma patients with locoregional metastases located in the pelvis subjected to melphalan hypoxic pelvic perfusion were examined. The methyla

SUBMITTER: Guadagni S 

PROVIDER: S-EPMC5592983 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature